美沙拉嗪联合双歧杆菌三联活菌散治疗溃疡性结肠炎临床疗效的Meta分析

Clinical efficacy of mesalazine combined with bifico for treatment of ulcerative colitis: a Meta-analysis

目的评价美沙拉嗪联合双歧杆菌三联活菌散治疗溃疡性结肠炎(UC)的临床疗效。方法计算机检索Cochrane、Pub Med、EMbase、中国生物医学文献、CNKI及维普等数据库,纳入有关美沙拉嗪联合双歧杆菌三联活菌散治疗UC的随机对照试验(RCT),筛选文献后对文献质量进行评价,采用Rev Man 5.3软件进行Meta分析。结果共纳入34篇RCT文献,共2 390例患者。Meta分析结果显示,联合用药组(美沙拉嗪及双歧杆菌三联活菌散)的总有效率高于单一用药组(美沙拉嗪)(P<0.05);治疗后联合用药组患者血清肿瘤坏死因子-α、白细胞介素-10及C反应蛋白、临床症状评分和内镜评分下降水平均高于单一用药组(均P<0.05)。结论采用联合口服美沙拉嗪和双歧杆菌三联活菌散治疗UC患者,可明显提高临床疗效,降低炎性指标水平。

Objective To evaluate the clinical efficacy of mesalazine combined with bifico for the treatment of ulcerative colitis （UC）. Methods The databases of computer retrieve included Cochrane, PubMed, EMbase, CBM, CNKI and VIP database. Randomized controlled trials（RCTs） about mesalazine combined with bifico for the treatment of UC were enrolled. The quality of literatures was assessed after screening. Meta-analysis was conducted using RevMan 5.3 software. Results Thirty-four RCTs consisting of 2 390 patients were included. The results of Meta-analysis showed that tbe total effective rate of the combination group （mesalazine combined with bifico） was higher than that of the single group （ mesalazine only） （ P 〈 0.05 ）. After treatment, the descent levels of serum tumor necrosis factor-or, interleukin-10, C-reactive protein, clinical symptom score and endoscopic score were higher in the combination group compared to the single group （ all P 〈 0.05 ）. Conclusion Oral administration of mesalazine and bifico for UC can significantly improve the clinical efficacy and reduce the levels of inflammatory indicators.